Safety profile of entrectinib in NSCLC: Multi-source pharmacovigilance analysis using FAERS and JADER
Background Entrectinib is effective for ROS1-positive non-small cell lung cancer (NSCLC), but its postmarketing safety profile remains incompletely characterized outside clinical trials. We conducted a dual-database pharmacovigilance study to characterize real-world reporting patterns, identify cross-database replicate...